118 completed, 32 terminated, 18 recruiting, 15 active not recruiting. 204 Phase 1, 76 Phase 2.
Follow Avastin: new trials by email Literature Review of Avastin trials Research Report on Avastin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases | Phase 1 / Phase 2 | Recruiting | Melanoma and Skin Cancer Trials Limited | 46 | 2026-08-31 | 2026-10-13 |
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma Sitagliptin, Bevacizumab - Glioma, Glioblastoma | Phase 1 | Recruiting | Kailin Yang, MD, PhD | 45 | 2026-06-11 | 2026-06-17 |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-07-22 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer Bevacizumab, Biospecimen Collection, Brachytherapy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 35 | 2025-07-29 | 2026-08-12 |
| Trial of ProAgio in Advanced/Metastatic Colorectal Cancer ProAgio, FOLFIRI, Bevacizumab - Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 1 | Suspended | University of Alabama at Birmingham | 27 | 2025-07-17 | 2026-10-02 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2025-06-23 | 2026-09-09 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT) - Hepatocellular Carcinoma (HCC), Macrovascular Invasion | Phase 1 / Phase 2 | Recruiting | University Health Network, Toronto | 48 | 2024-12-01 | 2024-12-16 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers 27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2024-08-06 | 2026-02-03 |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. PF-07934040, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Active not recruiting | Pfizer | 64 | 2024-06-27 | 2026-10-13 |
| Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer Liposomal irinotecan, Bevacizumab - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 74 | 2024-06-05 | 2024-05-30 |
| First In Human Study of CX-2051 in Advanced Solid Tumors CX-2051, Bevacizumab - Solid Tumor, Adult | Phase 1 | Recruiting | CytomX Therapeutics | 160 | 2024-04-02 | 2026-07-15 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors VVD-133214, Pembrolizumab, Bevacizumab - Advanced Solid Tumors, Colorectal Cancer | Phase 1 | Recruiting | Vividion Therapeutics, Inc. | 280 | 2024-01-25 | 2026-10-21 |
| A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tiragolumab - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 62 | 2023-12-05 | 2026-09-15 |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 622 | 2023-06-05 | 2026-10-05 |
Showing 20 of 204. Sign in to see all of them.
Colorectal Neoplasms (29) · Glioblastoma (26) · Neoplasms (16) · Ovarian Neoplasms (16) · Carcinoma, Non-Small-Cell Lung (15) · Carcinoma, Renal Cell (15) · Colonic Neoplasms (14) · Neoplasm Metastasis (14) · Brain Neoplasms (13) · Glioma (13) · Breast Neoplasms (11) · Fallopian Tube Neoplasms (11) · Rectal Neoplasms (11) · Pancreatic Neoplasms (10) · Astrocytoma (8)
M.D. Anderson Cancer Center (30) · National Cancer Institute (NCI) (28) · Hoffmann-La Roche (5) · Pfizer (4) · AstraZeneca (3) · City of Hope Medical Center (3) · Genentech, Inc. (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Massachusetts General Hospital (3) · Northwell Health (3) · SCRI Development Innovations, LLC (3) · CytomX Therapeutics (2) · Dana-Farber Cancer Institute (2) · Duke University (2) · Hellenic Oncology Research Group (2)
United States (167) · China (11) · Canada (9) · South Korea (9) · Australia (8) · France (8) · United Kingdom (8) · Spain (7) · Israel (6) · Germany (5) · Japan (5) · Taiwan (5) · Denmark (4) · Italy (4) · Belgium (3)
Apostolia M. Tsimberidou, MD, PhD (4) · Apostolia M. Tsimberidou, MD, PHD (3) · John Boockvar, MD (3) · Dimitris Mavrudis, MD (2) · Everett Vokes (2) · Funda Meric-Bernstam, MD (2) · Herbert I Hurwitz, MD (2) · Monika Vainorius, MD (2) · Patrick Y. Wen, MD (2) · Sunil Krishnan, MD (2) · Adam Cohen, MD (1) · Alain Mita (1) · Angeles A Secord, MD (1)
PMID 18272024, PMID 19201650, PMID 21984064, PMID 22200869, PMID 23615181, PMID 23756764, PMID 23777441, PMID 24091128, PMID 24158411, PMID 24173967, PMID 24422672, PMID 24481211, PMID 24912489, PMID 25001321, PMID 25572329, PMID 26172205, PMID 29153775, PMID 29695765, PMID 29887334, PMID 30053670, PMID 30185228, PMID 30302599, PMID 30347025, PMID 30402678, PMID 30603797, PMID 31697304, PMID 31708167, PMID 32097091, PMID 32324197, PMID 32337094, PMID 32771088, PMID 33099678, PMID 33142018, PMID 33610319, PMID 33616416, PMID 34164713, PMID 34189463, PMID 34359048, PMID 34555031, PMID 34913787, PMID 35116390, PMID 35756843, PMID 36183444, PMID 36459691, PMID 37311055, PMID 37651655, PMID 37939124, PMID 39572979, PMID 39855251, PMID 39863139
U01CA070095 (4), U10CA027469 (4), 2017 (3), U10CA180868 (3), 2009 (2), 2014 (2), 2023 (2), N01CM62201 (2), P30CA014599 (2), P30CA016672 (2), U01CA062490 (2), U01CA062491 (2), 2015 (1), 2025 (1), N01CM62204 (1)